Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

Anna Sophia McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara, Barbara Spitzer, Andrew M. Intlekofer, Jihae Ahn, Kaitlyn Shank, Franck T. Rapaport, Minal A. Patel, Efthymia Papalexi, Alan H. Shih, April Chiu, Elizaveta Freinkman, Esra A. Akbay, Mya Steadman, Raj Nagaraja, Katharine Yen, Julie Teruya-Feldstein, Kwok Kin Wong, Raajit RampalMatthew G. Vander Heiden, Craig B. Thompson, Ross L. Levine

Pathology
Pathology

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Sort by
Weight
Alphabetically

Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

Fingerprint

Medicine & Life Sciences